<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">STAR Protoc</journal-id><journal-id journal-id-type="iso-abbrev">STAR Protoc</journal-id><journal-title-group><journal-title>STAR Protocols</journal-title></journal-title-group><issn pub-type="epub">2666-1667</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39823234</article-id><article-id pub-id-type="pmc">PMC11786727</article-id><article-id pub-id-type="pii">S2666-1667(24)00713-5</article-id><article-id pub-id-type="doi">10.1016/j.xpro.2024.103548</article-id><article-id pub-id-type="publisher-id">103548</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Protocol for evaluating humoral immune responses in mice following SARS-CoV-2 vaccination</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Zhang</surname><given-names>Yao</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">5</xref><xref rid="fn2" ref-type="fn">6</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Li</surname><given-names>Shixiong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn1" ref-type="fn">5</xref><xref rid="fn2" ref-type="fn">6</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Yu</surname><given-names>Jingyou</given-names></name><email>yu_jingyou@gzlab.ac.cn</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="fn3" ref-type="fn">7</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China</aff><aff id="aff2"><label>2</label>Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China</aff><aff id="aff3"><label>3</label>College of Life Sciences, Nankai University, Tianjin 300071, China</aff><aff id="aff4"><label>4</label>State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>yu_jingyou@gzlab.ac.cn</email></corresp><fn id="fn1"><label>5</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>6</label><p id="ntpara0015">Technical contact</p></fn><fn id="fn3"><label>7</label><p id="ntpara0020">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>21</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2025</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>103548</elocation-id><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.</p><p>For complete details on the use and execution of this protocol, please refer to Jingyou Yu et&#x000a0;al.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Produce and purify an adenoviral-vectored vaccine for mouse immunization</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Measure binding antibody titers using ELISA from immunized mouse plasma</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Evaluate neutralizing antibody titers with a pseudovirus neutralization assay</p></list-item></list></p></abstract><abstract abstract-type="editor-highlights" id="abs0025"><p>Publisher&#x02019;s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.</p></abstract><abstract abstract-type="teaser" id="abs0030"><p>Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>cell biology</kwd><kwd>cell-based assays</kwd><kwd>immunology</kwd><kwd>microbiology</kwd><kwd>molecular biology</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Before you begin</title><sec id="sec1.1"><title>Institutional permission</title><p id="p0025">This protocol involves the use of female BALB/c mice aged 6&#x02013;8&#x000a0;weeks. All experiments must be conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) and in compliance with state and institutional regulations. These experimental procedures are certified by the AAALAC and conducted in a Specific Pathogen Free (SPF) laboratory animal facility.</p></sec><sec id="sec1.2"><title>Preparation 1: Adenoviral-vectored vaccine production</title><p id="p0030">
<disp-quote id="disp0010"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2</bold><bold>weeks</bold><bold>(for step 1)</bold></p></disp-quote>
<disp-quote id="disp0015"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 18&#x02013;36&#x000a0;days (for step 2)</bold></p></disp-quote>
<disp-quote id="disp0020"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 4&#x02013;6&#x000a0;days (for step 3a)</bold></p></disp-quote>
<disp-quote id="disp0025"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 4&#x02013;6&#x000a0;days (for step 3b)</bold></p></disp-quote>
<disp-quote id="disp0030"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x000a0;days (for steps 4&#x02013;8)</bold></p></disp-quote>
</p><p id="p0035">This step focuses on the production and purification of the adenoviral vectored vaccine in preparation for mouse immunization.<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0040">Clone the target gene encoding the spike protein of SARS-CoV-2 prototype strain WA01/2020 or EGFP into the pBR322-based adaptor plasmid pAdApt, using the Hind III and EcoR I restriction sites, driven by the cytomegalovirus (CMV) immediate-early promoter and terminated by an SV40 polyadenylation signal.</p></list-item><list-item id="o0015"><label>2.</label><p id="p0045">Adenovirus production.<list list-type="simple" id="olist0020"><list-item id="o0020"><label>a.</label><p id="p0050">Transfection Preparation.</p><p id="p01601a">Day 1.<list list-type="simple" id="olist0025"><list-item id="o0025"><label>i.</label><p id="p0055">Seed 2.5&#x000d7;10<sup>6</sup> HEK293A cells into T25 flasks.</p><p id="p0060">Day 2.</p></list-item><list-item id="o0030"><label>ii.</label><p id="p0065">Digest 2&#x000a0;&#x003bc;g of pAdApt and 6&#x000a0;&#x003bc;g of pWE plasmids using PacI restriction enzyme. Incubate at 37&#x000b0;C for 2&#x02013;3 h.<disp-quote id="disp0035"><p><bold><italic>Note:</italic></bold> After incubation, run 2&#x000a0;&#x003bc;L of the sample on an electrophoresis gel to verify complete digestion and confirm the correct band sizes. Linearized plasmids can be stored at &#x02212;20&#x000b0;C for a few days. Long-term storage is not recommended due to the low plasmids concentration in this system; any degradation could significantly affect subsequent steps.</p></disp-quote></p></list-item><list-item id="o0035"><label>iii.</label><p id="p0070">Dilute the plasmids and 24&#x000a0;&#x003bc;g PEI each in 500&#x000a0;&#x003bc;L of Opti-MEM. Mix the diluted PEI with the diluted plasmids solution and incubate at 25&#x000b0;C for 15&#x000a0;min. Transfect the linearized plasmids into HEK293A cells in the T25 flask.<disp-quote id="disp0040"><p><bold><italic>Note:</italic></bold> Ensure the cells are at 70%&#x02013;80% confluence before transfection.</p></disp-quote></p></list-item><list-item id="o0040"><label>iv.</label><p id="p0075">Incubate the flasks at 37&#x000b0;C with 5% CO<sub>2</sub> for 48 h.</p><p id="p0080">Day 4.</p></list-item></list></p></list-item><list-item id="o0045"><label>b.</label><p id="p0085">Use 0.05% trypsin-EDTA to detach the cells from the T25 flask. Transfer cells from the T25 flask to the T75 flask.</p><p id="p0090">Day 9&#x02013;36.</p></list-item><list-item id="o0050"><label>c.</label><p id="p0095">Observe for CPE (Cytopathic Effect) (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>A and 1B) between 5 to 14&#x000a0;days after transfer.<disp-quote id="disp0045"><p><bold><italic>Note:</italic></bold> After adenovirus replication, cytopathic effects (CPE) can be observed. In the early stages, a few cells exhibit rounding and detachment under the microscope, with a comet-tail appearance visible. As CPE progresses to full CPE, all cells become rounded and detached, though lysis has not yet occurred.</p></disp-quote></p></list-item><list-item id="o0055"><label>d.</label><p id="p0100">Once the CPE is evident, with most cells rounded and detached but not yet lysed, use a cell scraper to collect all the cells. The resulting mixture of cells and culture medium is referred to as the &#x0201c;crude culture.&#x0201d; Transfer the crude culture into a 15&#x000a0;mL tube for further processing.</p></list-item><list-item id="o0060"><label>e.</label><p id="p0105">Perform three freeze (&#x02212;20&#x000b0;C) and thaw (37&#x000b0;C) to release the virus.<disp-quote id="disp0050"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> If full CPE is observed, harvest the crude culture into a 15&#x000a0;mL tube and freeze at &#x02212;20&#x000b0;C, then thaw at 37&#x000b0;C, repeating the freeze-thaw cycle three times. If partial CPE is observed, follow the same harvesting and freeze-thaw process.</p></disp-quote></p><p id="p0110">Subsequently, centrifuge the crude lysate at 500 <italic>g</italic> for 5&#x000a0;min at 25&#x000b0;C and remove 2&#x000a0;mL of the supernatant to re-infect a T75 flask of HEK293A cells. If no CPE is observed by the time the cells die from overcrowding (approximately Day 14), harvest the crude culture and centrifuge as previously described, preparing for re-infection. If no full CPE is observed after two rounds of reinfection, proceed with re-transfection.<disp-quote id="disp0055"><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> Store crude culture at &#x02212;80&#x000b0;C for long-term storage.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0065"><label>3.</label><p id="p0115">Adenovirus expansion.<list list-type="simple" id="olist0035"><list-item id="o0070"><label>a.</label><p id="p0120">Expand Working Virus Seed Stock (WVSS).</p><p id="p0125">Day 1.<list list-type="simple" id="olist0040"><list-item id="o0075"><label>i.</label><p id="p0130">Seed 2&#x000d7;10<sup>7</sup> HEK 293A cells into the T175 flask.</p><p id="p0135">Day 2.</p></list-item><list-item id="o0080"><label>ii.</label><p id="p0140">Add 2&#x000a0;mL of viral stock into the T175 flask to infect the HEK 293A cells.<disp-quote id="disp0060"><p><bold><italic>Note:</italic></bold> Ensure the cells reach 70%&#x02013;80% confluence before viral infection.</p></disp-quote></p><p id="p0145">Day 4&#x0223c;6.</p></list-item><list-item id="o0085"><label>iii.</label><p id="p0150">Monitor for CPE. Harvest the crude cell culture on the day full CPE is observed. Collect the culture in a 50&#x000a0;mL tube, freeze at &#x02212;20&#x000b0;C, and then thaw at 37&#x000b0;C, repeating this freeze-thaw process three times. Centrifuge the crude lysate at 500 <italic>g</italic> for 5&#x000a0;min, and collect the supernatant, approximately 25&#x000a0;mL, to serve as the WVSS.<disp-quote id="disp0065"><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> Store WVSS at &#x02212;80&#x000b0;C for long-time storage.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0090"><label>b.</label><p id="p0155">Adenovirus expansion.</p><p id="p0160">Day 1.<list list-type="simple" id="olist0045"><list-item id="o0095"><label>i.</label><p id="p0165">Seed HEK 293A cells into five 5-layer T175 flasks.</p><p id="p0170">Day 2.</p></list-item><list-item id="o0100"><label>ii.</label><p id="p0175">Inoculate each 5-layer T175 flask with 4&#x000a0;mL of WVSS.<disp-quote id="disp0070"><p><bold><italic>Note:</italic></bold> Ensure the cells reach 70%&#x02013;80% confluence before viral infection.</p></disp-quote></p><p id="p0180">Day 4&#x0223c;6.</p></list-item><list-item id="o0105"><label>iii.</label><p id="p0185">Monitor for CPE. Harvest the cells and culture medium once complete CPE is observed. Collect in a 50&#x000a0;mL centrifuge tube, centrifuge at 500 <italic>g</italic> for 5&#x000a0;min, discard the supernatant, and transfer the cells into six 50&#x000a0;mL centrifuge tubes.</p></list-item><list-item id="o0110"><label>iv.</label><p id="p0190">Add 19&#x000a0;mL of 1&#x000d7; PBS to each tube and resuspend cells by pipetting.</p></list-item><list-item id="o0115"><label>v.</label><p id="p0195">Freeze the tubes at &#x02212;20&#x000b0;C.<disp-quote id="disp0075"><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> Store tubes at &#x02212;80&#x000b0;C for long-term storage.</p></disp-quote></p></list-item></list></p></list-item></list></p></list-item><list-item id="o0120"><label>4.</label><p id="p0200">Purification of adenoviral vectored vaccine.</p><p id="p0205">Day 1.<list list-type="simple" id="olist0055"><list-item id="o0125"><label>a.</label><p id="p0210">Lyse the cells.<list list-type="simple" id="olist0060"><list-item id="o0130"><label>i.</label><p id="p0215">Thaw the frozen production at 37&#x000b0;C until completely thawed.</p></list-item><list-item id="o0135"><label>ii.</label><p id="p0220">Add 2.25&#x000a0;mL of 5% sodium deoxycholate (DOC) to each tube to achieve a final concentration of 0.5% DOC. Homogenize the suspension by inverting 20 times.<disp-quote id="disp0080"><p><bold><italic>Note:</italic></bold> Avoid shaking; the mixture should appear thick and viscous.</p></disp-quote></p></list-item><list-item id="o0140"><label>iii.</label><p id="p0225">Incubate 37&#x000b0;C for 5&#x000a0;min, then homogenize by inverting 20 times.</p></list-item></list></p></list-item><list-item id="o0145"><label>b.</label><p id="p0230">Clarification.<list list-type="simple" id="olist0065"><list-item id="o0150"><label>i.</label><p id="p0235">Add 750&#x000a0;&#x003bc;L of 1&#x000a0;M MgCl<sub>2</sub> per tube and homogenize by inverting 20 times.<disp-quote id="disp0085"><p><bold><italic>Note:</italic></bold> Avoid shaking; a milky white precipitate should form.</p></disp-quote></p></list-item><list-item id="o0155"><label>ii.</label><p id="p0240">Add 80&#x000a0;&#x003bc;L 10&#x000a0;mg/mL DNase and homogenize by inverting 20 times.<disp-quote id="disp0090"><p><bold><italic>Note:</italic></bold> Avoid shaking.</p></disp-quote></p></list-item><list-item id="o0160"><label>iii.</label><p id="p0245">Incubate at 37&#x000b0;C for 15&#x000a0;min.<disp-quote id="disp0095"><p><bold><italic>Note:</italic></bold> A significant decrease in viscosity should be observed.</p></disp-quote></p></list-item><list-item id="o0165"><label>iv.</label><p id="p0250">Homogenize by inverting 20 times, then centrifuge at 12,000 <italic>g</italic> for 30&#x000a0;min to remove cell debris.<disp-quote id="disp0100"><p><bold><italic>Note:</italic></bold> Pour off the supernatant during this spin.</p></disp-quote></p></list-item><list-item id="o0170"><label>v.</label><p id="p0255">Transfer supernatant to new tubes.</p></list-item></list></p></list-item><list-item id="o0175"><label>c.</label><p id="p0260">CsCl Gradient Purification (Block Gradient).<list list-type="simple" id="olist0070"><list-item id="o0180"><label>i.</label><p id="p0265">Prepare the CsCl solution: Add 10&#x000a0;mL of 1.24 g/mL CsCl to ultracentrifuge tubes. Using a Pasteur pipette, carefully layer 5&#x000a0;mL of 1.4 g/mL CsCl at the bottom, followed by 23&#x02013;25&#x000a0;mL of the viral supernatant.<disp-quote id="disp0105"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Ensure the pipette touches the wall of the centrifuge tube to avoid disturbing the gradient.</p></disp-quote></p></list-item><list-item id="o0185"><label>ii.</label><p id="p0270">Balance the tubes to an accuracy of 0.01 g.</p></list-item><list-item id="o0190"><label>iii.</label><p id="p0275">Ultracentrifuge using an AH-629 swinging bucket rotor at 21,000&#x000a0;rpm (58,400 g) for 2&#x000a0;h at 10&#x000b0;C.</p></list-item><list-item id="o0195"><label>iv.</label><p id="p0280">Prepare a stand with clamp and black background over bucket of 10% SDS.</p></list-item><list-item id="o0200"><label>v.</label><p id="p0285">Use a 0.9&#x02013;40&#x000a0;mm needle and 10&#x000a0;mL syringe to puncture the tube wall at an upward angle and carefully extract the viral band into a new tube.<disp-quote id="disp0110"><p><bold><italic>Note:</italic></bold> White or blue virus band should be visible between 1.24 and 1.4 g/mL layers (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). No bands should be found beneath the virus band, while the band above contains empty capsids, and the one above that contains hexon protein.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0205"><label>d.</label><p id="p0290">CsCl Gradient Purification (Continuous Gradient).<list list-type="simple" id="olist0075"><list-item id="o0210"><label>i.</label><p id="p0295">Transfer the collected viral liquid into 13.2&#x000a0;mL ultracentrifuge tubes, adding up to 7&#x000a0;mL in each. Add 1.33 g/mL CsCl, balance the tubes, and ultracentrifuge using a TH-641 swinging bucket rotor at 55,000&#x000a0;rpm (260,000 g) at 4&#x000b0;C for 10&#x02013;18 h.</p><p id="p0300">Day 2.</p></list-item><list-item id="o0215"><label>ii.</label><p id="p0305">Prepare a stand with clamp and black background over bucket of 10% SDS.</p></list-item><list-item id="o0220"><label>iii.</label><p id="p0310">Use a 0.9&#x02013;40&#x000a0;mm needle and 10&#x000a0;mL syringe to puncture the tube wall at an upward angle and carefully extract the viral band to a new tube.</p></list-item><list-item id="o0225"><label>iv.</label><p id="p0315">Extract lowest virus band (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D) with the needle and syringe, aiming to minimize the liquid volume collected.<disp-quote id="disp0115"><p><bold><italic>Note:</italic></bold> The virus band is located in the middle of the tube; the upper bands contain empty capsids and hexon protein.</p></disp-quote></p></list-item></list></p></list-item></list></p></list-item><list-item id="o0230"><label>5.</label><p id="p0320">Dialysis.<list list-type="simple" id="olist0085"><list-item id="o0235"><label>a.</label><p id="p0325">Prepare dialysis buffer 1, 2 and 3.</p></list-item><list-item id="o0240"><label>b.</label><p id="p0330">Use a clean, autoclaved 3&#x000a0;L beaker with stir bar in hood, add 1.5&#x000a0;L dialysis buffer 1.</p></list-item><list-item id="o0245"><label>c.</label><p id="p0335">Place the CsCl-virus mixture into a dialysis membrane and secure it with dialysis clips.<disp-quote id="disp0120"><p><bold><italic>Note:</italic></bold> The dialysis membrane has a 10&#x000a0;kDa cutoff and is suitable for a sample volume of 3&#x02013;15&#x000a0;mL.</p></disp-quote></p></list-item><list-item id="o0250"><label>d.</label><p id="p0340">Place the dialysis membrane into a beaker containing dialysis buffer 1 and stir at 200&#x000a0;rpm at 25&#x000b0;C for 1&#x000a0;h of dialysis.</p></list-item><list-item id="o0255"><label>e.</label><p id="p0345">Replace buffer 1 with buffer 2 and continue dialysis for an additional hour.</p></list-item><list-item id="o0260"><label>f.</label><p id="p0350">Replace buffer 2 with buffer 3 and continue dialysis for the final hour.</p></list-item><list-item id="o0265"><label>g.</label><p id="p0355">Transfer the virus into a 50&#x000a0;mL tube.</p></list-item></list></p></list-item><list-item id="o0270"><label>6.</label><p id="p0360">Aliquot the appropriate volume of purified virus into 1.5&#x000a0;mL Eppendorf tubes and store at &#x02212;80&#x000b0;C for long-term storage.</p></list-item><list-item id="o0275"><label>7.</label><p id="p0365">Use the primer pair pAdapt-PF and pAdapt-PR to perform qPCR for determining the viral particle (vp) titers.</p></list-item><list-item id="o0280"><label>8.</label><p id="p0370">Infect the A549 cell line with purified adenovirus at a dose of 5 MOI. After 48 h, observe EGFP protein expression under a fluorescence microscope (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E) and verify S protein expression by Western blotting (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F).</p></list-item></list><disp-quote id="disp0125"><p><bold><italic>Note:</italic></bold> All items that come into direct contact with the adenovirus during these steps must be wiped or soaked with 1% SDS to inactivate the virus.</p></disp-quote><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Production, purification, and expression of adenoviral vectored vaccines</p><p>After transferring the HEK 293A cells packaging adenovirus to a T75 flask, CPE are observed between days 5 and 14.</p><p>(A) Ad5-EGFP, (B) Ad5-S.</p><p>(C) CsCl Gradient Purification (Block Gradient).</p><p>(D) CsCl Gradient Purification (Continuous Gradient). The red arrow indicates the adenovirus band.</p><p>(E) Fluorescence microscopy of A549 cells infected by Ad5-EGFP after 48 h.</p><p>(F) Western blot (WB) analysis detecting spike protein expression in A549 cells 48&#x000a0;h post-infection with Ad5-EGFP/S viruses. Scale bars represent 200&#x000a0;&#x003bc;m.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec1.3"><title>Preparation 2: Mice immunization</title><p id="p0375">
<disp-quote id="disp0130"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 4&#x000a0;weeks</bold></p></disp-quote>
</p><p id="p0380">This step mainly involves immunizing BALB/c mice with adenovirus-vectored vaccines via intramuscular injection to evaluate the humoral immune response.<list list-type="simple" id="olist0095"><list-item id="o0285"><label>9.</label><p id="p0385">Maintain specific pathogen-free 6- to 8-week-old BALB/c mice in the Animal Care Facilities, randomly allocating 5 mice per cage.</p></list-item><list-item id="o0290"><label>10.</label><p id="p0390">Immunize the mice with 1&#x000a0;&#x000d7;&#x000a0;10<sup>8</sup> vp adenoviral-vectored vaccines in a total volume of 100&#x000a0;&#x003bc;L, administered through bilateral intramuscular injection into the quadriceps muscles (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).</p></list-item></list><disp-quote id="disp0135"><p><bold><italic>Note:</italic></bold> Avoid repeated freezing and thawing of vaccines.</p></disp-quote><list list-type="simple" id="olist0100"><list-item id="o0295"><label>11.</label><p id="p0395">Four weeks after the vaccination, collect 100&#x02013;200&#x000a0;&#x003bc;L peripheral blood via the submandibular route and isolate plasma for immunological assays by centrifuging at 1,000 <italic>g</italic> at 25&#x000b0;C for 10&#x000a0;min.</p></list-item></list><disp-quote id="disp0140"><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> Plasma can be frozen and stored at &#x02212;80&#x000b0;C for long-term use.</p></disp-quote><table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Ad5-vectored vaccines preparation for mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Group vaccine</th><th>Concentration</th><th>Total volume</th><th>Mice</th></tr></thead><tbody><tr><td>1</td><td>Ad5-EGFP</td><td>1&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup> vp/mL</td><td>500&#x000a0;&#x003bc;L</td><td>5</td></tr><tr><td>2</td><td>Ad5-S</td><td>1&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup> vp/mL</td><td>500&#x000a0;&#x003bc;L</td><td>5</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec2"><title>Key resources table</title><p id="p0400">
<table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Goat anti-mouse IgG-HRP (1:4,000)</td><td>Sino Biological</td><td>Cat# SSA007</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Biological samples</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Mice plasma</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Pac&#x02160;</td><td>NEB</td><td>Cat# R0547</td></tr><tr><td>Sodium deoxycholate (DOC)</td><td>Sigma</td><td>Cat# D6750</td></tr><tr><td>1&#x000a0;M MgCl<sub>2</sub></td><td>LEAGENE</td><td>Cat# R00482</td></tr><tr><td>DNase&#x02160;</td><td>Roche</td><td>Cat# 104159</td></tr><tr><td>CsCl</td><td>Macklin</td><td>Cat# C804679</td></tr><tr><td>MgCl<sub>2</sub>&#x000b7;6H<sub>2</sub>O</td><td>Sigma</td><td>Cat# M2393</td></tr><tr><td>CaCl<sub>2</sub>&#x000b7;2H<sub>2</sub>O</td><td>Sigma</td><td>Cat# C7902</td></tr><tr><td>Sucrose</td><td>Macklin</td><td>Cat# S818046</td></tr><tr><td>1&#x000a0;M Tris HCl pH 7.5</td><td>Yuanye</td><td>Cat# R21385</td></tr><tr><td>Glycerol</td><td>Macklin</td><td>Cat# G810575</td></tr><tr><td>Imidazole</td><td>Solarbio</td><td>Cat# 288-32-4</td></tr><tr><td>Protease inhibitor cocktail</td><td>MCE</td><td>Cat# HY-K0010</td></tr><tr><td>Amicon Ultra column</td><td>MCE</td><td>Cat# UFC9030</td></tr><tr><td>ELISAcoating buffer</td><td>Solarbio</td><td>Cat# C1050</td></tr><tr><td>Difco Skim milk</td><td>BD Life Sciences</td><td>Cat# 90002-594</td></tr><tr><td>Tween 20</td><td>Diamond</td><td>Cat# A100777- 0500</td></tr><tr><td>TMB</td><td>Solarbio</td><td>Cat# PR1200</td></tr><tr><td>ELISA Stop buffer</td><td>Solarbio</td><td>Cat# C1058</td></tr><tr><td>PEI</td><td>Polysciences</td><td>Cat# 23966</td></tr><tr><td>CD 293 TGE medium</td><td>ACROBiosystems</td><td>Cat# CM-1156-11</td></tr><tr><td>High-affinity Ni-NTA resin</td><td>GenScript</td><td>Cat# L00250</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>Biosharp</td><td>Cat# BL302A</td></tr><tr><td>0.05% trypsin-EDTA</td><td>Gibco</td><td>Cat# 25300062</td></tr><tr><td>DMEM</td><td>Gibco</td><td>Cat# C11995500BT</td></tr><tr><td>FBS</td><td>ExCell Bio</td><td>Cat# FSP500</td></tr><tr><td>Opti-MEM I reduced serum medium</td><td>Gibco</td><td>Cat# 31985070</td></tr><tr><td>Firefly Luciferase Reporter Gene Assay Kit</td><td>Beyotime</td><td>Cat# RG006</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models: Cell lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>HEK 293A</td><td>This paper</td><td>N/A</td></tr><tr><td>A549</td><td>This paper</td><td>N/A</td></tr><tr><td>HEK 293F</td><td>This paper</td><td>N/A</td></tr><tr><td>HEK 293T</td><td>ATCC</td><td>Cat# CRL-11268</td></tr><tr><td>HEK 293T-ACE2</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>BALB/c mice, 6&#x02013;8&#x000a0;weeks old, female</td><td>Beijing Vital River Laboratory Animal Technology Co., Ltd.</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>pAdApt-PF</td><td>GCCGGGAACGGTGC ATTGGA</td><td>N/A</td></tr><tr><td>pAdApt-PR</td><td>GAGGATCCGTTAAC GCTAGC</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Recombinant DNA</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>pcDNA3.1-spike RBD</td><td>This paper</td><td>N/A</td></tr><tr><td>PsPAX2</td><td>Addgene</td><td>Cat# 12260</td></tr><tr><td>pLenti-CMV Puro-Luc</td><td>Addgene</td><td>Cat# 17477</td></tr><tr><td>pcDNA3.1-S.dCT13</td><td>This paper</td><td>N/A</td></tr><tr><td>pWE.Ad.AflII-rITR.dE3</td><td>This paper</td><td>N/A</td></tr><tr><td>pAdApt-EGFP</td><td>This paper</td><td>N/A</td></tr><tr><td>pAdApt-S WA01/2020</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>GraphPad Prism 9.0.0</td><td>GraphPad Software, Inc.</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/" id="intref0010">https://www.graphpad.com/</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Other</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>T25 flask</td><td>NEST</td><td>Cat# 707003</td></tr><tr><td>T75 flask</td><td>NEST</td><td>Cat# 708003</td></tr><tr><td>T175 flask</td><td>NEST</td><td>Cat# 709003</td></tr><tr><td>5-layer flask</td><td>NEST</td><td>Cat# 731002</td></tr><tr><td>38.5&#x000a0;mL ultracentrifuge tube</td><td>Beckman</td><td>Cat# 344058</td></tr><tr><td>13.2&#x000a0;mL ultracentrifuge tube</td><td>Beckman</td><td>Cat# 344059</td></tr><tr><td>10&#x000a0;kDa cut-off dialysis membrane</td><td>Yuanye</td><td>Cat# SP131276</td></tr><tr><td>Sealing film</td><td>Solarbio</td><td>Cat# YA0247</td></tr><tr><td>96-well tissue culture plate</td><td>NEST</td><td>Cat# 701001</td></tr><tr><td>96-well EIA/RIA plate</td><td>Corning</td><td>Cat# 3590</td></tr><tr><td>96-well round bottom plate</td><td>Corning</td><td>Cat# 3799</td></tr><tr><td>White plate</td><td>Corning</td><td>Cat# 3922</td></tr><tr><td>High-affinity Ni-NTA resin</td><td>GenScript</td><td>Cat# L00250</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec3"><title>Materials and equipment</title><p id="p0405">
<table-wrap position="float" id="undtbl2"><caption><p>Digestion of pAdApt</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>pAdApt</td><td>2&#x000a0;&#x003bc;g</td><td>X &#x003bc;L</td></tr><tr><td>10&#x000a0;&#x000d7;&#x000a0;rCutSmart buffer</td><td>N/A</td><td>3&#x000a0;&#x003bc;L</td></tr><tr><td>PacI</td><td>20&#x000a0;U</td><td>2&#x000a0;&#x003bc;L</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>25-X</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>30&#x000a0;&#x003bc;L</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0145"><p><bold><italic>Note:</italic></bold> After digestion, heat inactivate and sterilize at 65&#x000b0;C for 30&#x000a0;min.</p></disp-quote>
<table-wrap position="float" id="undtbl3"><caption><p>Digestion of pAdApt</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>pWE</td><td>6&#x000a0;&#x003bc;g</td><td>X &#x003bc;L</td></tr><tr><td>10&#x000a0;&#x000d7;&#x000a0;rCutSmart buffer</td><td>N/A</td><td>3&#x000a0;&#x003bc;L</td></tr><tr><td>PacI</td><td>60&#x000a0;U</td><td>6&#x000a0;&#x003bc;L</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>21-X</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>30&#x000a0;&#x003bc;L</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0150"><p><bold><italic>Note:</italic></bold> After digestion, heat inactivate and sterilize at 65&#x000b0;C for 30&#x000a0;min.</p></disp-quote>
<table-wrap position="float" id="undtbl4"><caption><p>5% DOC</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th><th>Concentration</th></tr></thead><tbody><tr><td>Sodium deoxycholate (DOC)</td><td>5 g</td><td>N/A</td><td>5%</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>100&#x000a0;mL</td><td>N/A</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>100&#x000a0;mL</bold></td><td><bold>N/A</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0155"><p><bold><italic>Note:</italic></bold> Sterilized by filtration. Store at RT for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl5"><caption><p>10&#x000a0;mg/mL DNase I</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th><th>Concentration</th></tr></thead><tbody><tr><td>DNase I</td><td>100&#x000a0;mg</td><td>N/A</td><td>10&#x000a0;mg/mL</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>10&#x000a0;mL</td><td>N/A</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>10&#x000a0;mL</bold></td><td><bold>N/A</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0160"><p><bold><italic>Note:</italic></bold> Store at &#x02212;20&#x000b0;C for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl6"><caption><p>1.2 g/mL CsCl, 5% v/v glycerol in 25&#x000a0;mM Tris pH 7.5</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>CsCl</td><td>278 g</td><td>N/A</td></tr><tr><td>1&#x000a0;M Tris HCl pH 7.5</td><td>N/A</td><td>30&#x000a0;mL</td></tr><tr><td>Glycerol</td><td>N/A</td><td>50&#x000a0;mL</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>920&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1000&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0165"><p><bold><italic>Note:</italic></bold> Dissolve 278&#x000a0;g CsCl in 700&#x000a0;mL ddH<sub>2</sub>O, add 30&#x000a0;mL 1&#x000a0;M Tris HCl pH 7.5 and 50&#x000a0;mL glycerol, add ddH<sub>2</sub>O to 1000&#x000a0;mL, weigh 1&#x000a0;mL solution, adjust weight to 1.2&#x000a0;g by adding CsCl or ddH<sub>2</sub>O. Store at RT for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl7"><caption><p>1. 4 g/mL CsCl, 5% v/v glycerol in 25&#x000a0;mM Tris pH 7.5</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>CsCl</td><td>478 g</td><td>N/A</td></tr><tr><td>1&#x000a0;M Tris HCl pH 7.5</td><td>N/A</td><td>30&#x000a0;mL</td></tr><tr><td>Glycerol</td><td>N/A</td><td>50&#x000a0;mL</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>920&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1000&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0170"><p><bold><italic>Note:</italic></bold> Dissolve 478&#x000a0;g CsCl in 700&#x000a0;mL ddH<sub>2</sub>O, add 30&#x000a0;mL 1&#x000a0;M Tris HCl pH 7.5 and 50&#x000a0;mL glycerol, add ddH<sub>2</sub>O to 1000&#x000a0;mL, weigh 1&#x000a0;mL solution, adjust weight to 1.4&#x000a0;g by adding CsCl or ddH<sub>2</sub>O. Store at RT for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl8"><caption><p>1.24 g/mL CsCl, 5% v/v glycerol in 25&#x000a0;mM Tris pH 7.5</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>CsCl</td><td>318 g</td><td>N/A</td></tr><tr><td>1&#x000a0;M Tris HCl pH 7.5</td><td>N/A</td><td>30&#x000a0;mL</td></tr><tr><td>Glycerol</td><td>N/A</td><td>50&#x000a0;mL</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>920&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1000&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0175"><p><bold><italic>Note:</italic></bold> Dissolve 318&#x000a0;g CsCl in 700&#x000a0;mL ddH<sub>2</sub>O, add 30&#x000a0;mL 1&#x000a0;M Tris HCl pH 7.5 and 50&#x000a0;mL glycerol, add ddH<sub>2</sub>O to 1000&#x000a0;mL, weigh 1&#x000a0;mL solution, adjust weight to 1.24&#x000a0;g by adding CsCl or ddH<sub>2</sub>O. Store at RT for 1 year.</p></disp-quote>
<disp-quote id="disp0180"><p><bold><italic>Alternative:</italic></bold> 800&#x000a0;mL 1.2 g/mL CsCl plus 200&#x000a0;mL 1.4 g/mL CsCl.</p></disp-quote>
<table-wrap position="float" id="undtbl9"><caption><p>1.33 g/mL CsCl, 5% v/v glycerol in 25&#x000a0;mM Tris pH 7.5</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>CsCl</td><td>408 g</td><td>N/A</td></tr><tr><td>1&#x000a0;M Tris HCl pH 7.5</td><td>N/A</td><td>30&#x000a0;mL</td></tr><tr><td>Glycerol</td><td>N/A</td><td>50&#x000a0;mL</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>920&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1000&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0185"><p><bold><italic>Note:</italic></bold> Dissolve 408&#x000a0;g CsCl in 700&#x000a0;mL ddH<sub>2</sub>O, add 30&#x000a0;mL 1&#x000a0;M Tris HCl pH 7.5 and 50&#x000a0;mL glycerol, add ddH<sub>2</sub>O to 1000&#x000a0;mL, weigh 1&#x000a0;mL solution, adjust weight to 1.33&#x000a0;g by adding CsCl or ddH<sub>2</sub>O. Store at RT for 1 year.</p></disp-quote>
<disp-quote id="disp0190"><p><bold><italic>Alternative:</italic></bold> 350&#x000a0;mL 1.2 g/mL CsCl plus 650&#x000a0;mL 1.4 g/mL CsCl.</p></disp-quote>
<table-wrap position="float" id="undtbl10"><caption><p>50% sucrose</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th><th>Concentration</th></tr></thead><tbody><tr><td>Sucrose</td><td>250 g</td><td>N/A</td><td>50%</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>500&#x000a0;mL</td><td>N/A</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>500&#x000a0;mL</bold></td><td><bold>N/A</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0195"><p><bold><italic>Note:</italic></bold> Make up to 500&#x000a0;mL with ddH<sub>2</sub>O and autoclave at 121&#x000b0;C for 15&#x000a0;min. Store at RT for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl11"><caption><p>200&#x000a0;&#x000d7;&#x000a0;Ca-MgCl<sub>2</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th></tr></thead><tbody><tr><td>MgCl<sub>2</sub>&#x000b7;6H<sub>2</sub>O</td><td>13.25 g</td><td>N/A</td></tr><tr><td>CaCl<sub>2</sub>&#x000b7;2H<sub>2</sub>O</td><td>10 g</td><td>N/A</td></tr><tr><td>ddH<sub>2</sub>O</td><td>N/A</td><td>500&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>500&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0200"><p><bold><italic>Note:</italic></bold> Autoclave at 121&#x000b0;C for 15&#x000a0;min. Store at RT for 1 year.</p></disp-quote>
<table-wrap position="float" id="undtbl12"><caption><p>Dialysis buffer 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Volume</th></tr></thead><tbody><tr><td>50% sucrose</td><td>30&#x000a0;mL</td></tr><tr><td>200&#x000a0;&#x000d7;&#x000a0;CaMgCl<sub>2</sub></td><td>7.5&#x000a0;mL</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>1500&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>1537.5&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0205"><p><bold><italic>Note:</italic></bold> Prepare fresh.</p></disp-quote>
<table-wrap position="float" id="undtbl13"><caption><p>Dialysis buffer 2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Volume</th></tr></thead><tbody><tr><td>50% sucrose</td><td>60&#x000a0;mL</td></tr><tr><td>200&#x000a0;&#x000d7;&#x000a0;CaMgCl<sub>2</sub></td><td>7.5&#x000a0;mL</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>1500&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>1567.5&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0210"><p><bold><italic>Note:</italic></bold> Prepare fresh.</p></disp-quote>
<table-wrap position="float" id="undtbl14"><caption><p>Dialysis buffer 3</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Volume</th></tr></thead><tbody><tr><td>50% sucrose</td><td>90&#x000a0;mL</td></tr><tr><td>200&#x000a0;&#x000d7;&#x000a0;CaMgCl<sub>2</sub></td><td>7.5&#x000a0;mL</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>1500&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>1597.5&#x000a0;mL</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0215"><p><bold><italic>Note:</italic></bold> Prepare fresh.</p></disp-quote>
<table-wrap position="float" id="undtbl15"><caption><p>Block buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Amount</th><th>Volume</th><th>Concentration</th></tr></thead><tbody><tr><td>Skim milk</td><td>0.5 g</td><td>N/A</td><td>5%</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>N/A</td><td>10&#x000a0;mL</td><td>N/A</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>10&#x000a0;mL</bold></td><td><bold>N/A</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0220"><p><bold><italic>Note:</italic></bold> Prepare fresh.</p></disp-quote>
<table-wrap position="float" id="undtbl16"><caption><p>Wash buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Volume</th><th>Concentration</th></tr></thead><tbody><tr><td>Tween 20</td><td>0.5&#x000a0;mL</td><td>0.05%</td></tr><tr><td>1&#x000a0;&#x000d7;&#x000a0;PBS</td><td>1000&#x000a0;mL</td><td>N/A</td></tr><tr><td><bold>Total</bold></td><td><bold>1000&#x000a0;mL</bold></td><td><bold>N/A</bold></td></tr></tbody></table></table-wrap>
<disp-quote id="disp0225"><p><bold><italic>Note:</italic></bold> Store at RT for 1&#x000a0;week.</p></disp-quote>
</p></sec><sec id="sec4"><title>Step-by-step method details</title><sec id="sec4.1"><title>Spike protein production and purification</title><p id="p0410">
<disp-quote id="disp0230"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 7&#x02013;8&#x000a0;days</bold></p></disp-quote>
</p><p id="p0415">This step mainly involves the production and purification of the Spike RBD protein, which is used to measure antibody titers in the plasma of immunized mice.<list list-type="simple" id="olist0105"><list-item id="o0300"><label>1.</label><p id="p0420">The RBD protein is produced in-house.</p></list-item><list-item id="o0305"><label>2.</label><p id="p0425">The codon-optimized DNA encoding SARS-CoV-2 RBD is artificially synthesized and subcloned into a pcDNA3.1 vector with a 6&#x000a0;&#x000d7;&#x000a0;His tag at the C-terminus using the HindIII and EcoRI restriction sites.</p></list-item><list-item id="o0310"><label>3.</label><p id="p0430">Seed HEK-293F cells at a density of 0.5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells/mL in 400&#x000a0;mL of CD 293 TGE Medium in a 1&#x000a0;L shaker flask.</p></list-item><list-item id="o0315"><label>4.</label><p id="p0435">Incubate for 24&#x000a0;h in an orbital shaker at 37&#x000b0;C, 150&#x000a0;rpm, and 5% CO<sub>2</sub> until the cells reach a density of 2.0&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells/mL with 95%&#x0223c;98% viability.</p></list-item><list-item id="o0320"><label>5.</label><p id="p0440">Dilute 400&#x000a0;&#x003bc;g of filter-sterilized RBD plasmid DNA into 20&#x000a0;mL of CD 293 TGE Medium and vortex for 5 s.</p></list-item><list-item id="o0325"><label>6.</label><p id="p0445">Add 1.2&#x000a0;mL of filter-sterilized 1&#x000a0;mg/mL PEI solution to the plasmid DNA solution, vortex vigorously for 5 s, mix well, and incubate at 25&#x000b0;C for 20&#x000a0;min.</p></list-item><list-item id="o0330"><label>7.</label><p id="p0450">Transfer DNA/PEI mixed solution into 400&#x000a0;mL of HEK-293F cells and incubate the cells in an orbital shaker at 37&#x000b0;C with 5% CO<sub>2</sub> for 5&#x000a0;days.</p></list-item><list-item id="o0335"><label>8.</label><p id="p0455">Harvest the culture medium by centrifugation at 12,000 <italic>g</italic> for 15&#x000a0;min and filter the supernatant through a 0.22&#x000a0;&#x003bc;m filter.</p></list-item><list-item id="o0340"><label>9.</label><p id="p0460">Adjust the pH of the supernatant to 7.4 using 1&#x000a0;M Tris-HCl (pH&#x000a0;= 8) and then use a peristaltic pump to pass the medium through a His GraviTrap column while on ice.</p></list-item><list-item id="o0345"><label>10.</label><p id="p0465">Wash the column with 50 column volumes of wash buffer (1&#x000a0;&#x000d7;&#x000a0;PBS contains 20&#x000a0;mM imidazole).</p></list-item><list-item id="o0350"><label>11.</label><p id="p0470">Elute the HisTrap column with 2 column volumes elution buffer (1&#x000a0;&#x000d7;&#x000a0;PBS contains 100/200/300&#x000a0;mM imidazole, respectively).</p></list-item><list-item id="o0355"><label>12.</label><p id="p0475">Collect the high purity protein and exchange the buffer to 1&#x000a0;&#x000d7;&#x000a0;PBS using a 10&#x000a0;kDa Amicon Ultra column.</p></list-item><list-item id="o0360"><label>13.</label><p id="p0480">Collect and concentrate the protein, then store it at &#x02212;80&#x000b0;C.</p></list-item></list></p></sec><sec id="sec4.2"><title>ELISA process</title><p id="p0485">
<disp-quote id="disp0235"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x000a0;days</bold></p></disp-quote>
</p><p id="p0490">This step focuses on measuring the antibody titers in the plasma of mice immunized with the adenoviral vector vaccine using an enzyme-linked immunosorbent assay (ELISA).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Plasma dilution for the ELISA assay</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Sample ID</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th><th>NC -</th></tr></thead><tbody><tr><td><bold>A</bold></td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>1:100</td><td>N/A</td></tr><tr><td><bold>B</bold></td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>1:300</td><td>N/A</td></tr><tr><td><bold>C</bold></td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>1:900</td><td>N/A</td></tr><tr><td><bold>D</bold></td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>1:2700</td><td>N/A</td></tr><tr><td><bold>E</bold></td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>1:8100</td><td>N/A</td></tr><tr><td><bold>F</bold></td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>1:24300</td><td>N/A</td></tr><tr><td><bold>G</bold></td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>1:72900</td><td>N/A</td></tr><tr><td><bold>H</bold></td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>1:218100</td><td>N/A</td></tr></tbody></table><table-wrap-foot><fn><p>NC for negative control.</p></fn></table-wrap-foot></table-wrap></p><p id="p0495">Day 1.<list list-type="simple" id="olist0110"><list-item id="o0365"><label>14.</label><p id="p0500">Coat ELISA plates.<list list-type="simple" id="olist0115"><list-item id="o0370"><label>a.</label><p id="p0505">Thaw the RBD protein, mix gently, and dilute in 1&#x000a0;&#x000d7;&#x000a0;PBS to a final concentration of 1&#x000a0;&#x003bc;g/mL for coating 96-well ELISA plates.</p></list-item><list-item id="o0375"><label>b.</label><p id="p0510">Using a multichannel pipette, add 100&#x000a0;&#x003bc;L of diluted protein to each well, ensuring to cover the bottom of the plate thoroughly. Cover the plates with plastic covers and store 12&#x000a0;h at 4&#x000b0;C.</p></list-item></list></p></list-item></list><disp-quote id="disp0240"><p><bold><italic>Note:</italic></bold> Slightly increase the volume if necessary, when using the multichannel pipette.</p></disp-quote></p><p id="p0515">Day 2.<list list-type="simple" id="olist0120"><list-item id="o0380"><label>15.</label><p id="p0520">Block ELISA plates.<list list-type="simple" id="olist0125"><list-item id="o0385"><label>a.</label><p id="p0525">Prepare at least 10&#x000a0;mL block buffer per plate.</p></list-item><list-item id="o0390"><label>b.</label><p id="p0530">Wash the coated ELISA plates three times with 300&#x000a0;&#x003bc;L of 0.05% PBST using a 96-well dispenser.</p></list-item><list-item id="o0395"><label>c.</label><p id="p0535">Add 100&#x000a0;&#x003bc;L of blocking solution to each well and incubate at 25&#x000b0;C for 2&#x000a0;h shaking at 100&#x000a0;rpm.</p></list-item></list></p></list-item><list-item id="o0400"><label>16.</label><p id="p0540">Pre-dilute plasma.<list list-type="simple" id="olist0135"><list-item id="o0405"><label>a.</label><p id="p0545">Set up 96-well round-bottom cell culture plates for 3-fold serial dilution of samples.</p></list-item><list-item id="o0410"><label>b.</label><p id="p0550">Using a multichannel pipettor, add 120&#x000a0;&#x003bc;L of PBS containing 1% milk to all wells, and add an additional 78&#x000a0;&#x003bc;L to the wells in line A only.</p></list-item><list-item id="o0415"><label>c.</label><p id="p0555">Add 2&#x000a0;&#x003bc;L plasma to line A and pipette up and down four to six times to mix.<disp-quote id="disp0245"><p><bold><italic>Note:</italic></bold> The dilution ratio for plasma samples in line A is 1:100.</p></disp-quote></p></list-item><list-item id="o0420"><label>d.</label><p id="p0560">Transfer 60&#x000a0;&#x003bc;L (3-fold dilution) from line A to line B and mix well. Repeat this process through line H, discarding 60&#x000a0;&#x003bc;L from line H (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).</p></list-item></list></p></list-item><list-item id="o0425"><label>17.</label><p id="p0565">Incubate samples and secondary antibody (HRP).<list list-type="simple" id="olist0145"><list-item id="o0430"><label>a.</label><p id="p0570">After blocking, discard the blocking solution and wash the plates twice with 200&#x000a0;&#x003bc;L 0.05% PBST.</p></list-item><list-item id="o0435"><label>b.</label><p id="p0575">Add 100&#x000a0;&#x003bc;L sample to the corresponding wells in order, from the lowest to the highest concentration.</p></list-item><list-item id="o0440"><label>c.</label><p id="p0580">Seal the plates and incubate for 2&#x000a0;h at 25&#x000b0;C.</p></list-item><list-item id="o0445"><label>d.</label><p id="p0585">After incubation, wash the plates 5 times with 200&#x000a0;&#x003bc;L of 0.05% PBST.</p></list-item><list-item id="o0450"><label>e.</label><p id="p0590">For IgG plates, dilute goat anti-mouse IgG-HRP detection antibody to a final concentration of 0.25&#x000a0;&#x003bc;g/mL in PBS with 1% milk.</p></list-item><list-item id="o0455"><label>f.</label><p id="p0595">Seal the plates and incubate for 1&#x000a0;h at 25&#x000b0;C.</p></list-item><list-item id="o0460"><label>g.</label><p id="p0600">After incubation, wash the plates 5 times with 200&#x000a0;&#x003bc;L of 0.05% PBST.</p></list-item></list></p></list-item><list-item id="o0465"><label>18.</label><p id="p0605">Incubate substrate and measure absorbance.<list list-type="simple" id="olist0150"><list-item id="o0470"><label>a.</label><p id="p0610">Add 100&#x000a0;&#x003bc;L one-component TMB substrate to each well and incubate for 3&#x02013;5&#x000a0;min in the dark at 25&#x000b0;C.</p></list-item><list-item id="o0475"><label>b.</label><p id="p0615">Add 50&#x000a0;&#x003bc;L of stop solution to each well.</p></list-item><list-item id="o0480"><label>c.</label><p id="p0620">Measure absorbance at 450&#x000a0;nm using the plate reader and Gen5 software.</p></list-item></list></p></list-item></list><disp-quote id="disp0250"><p><bold><italic>Note:</italic></bold> Allow the TMB substrate solution to reach 25&#x000b0;C before adding it to the wells.</p></disp-quote><list list-type="simple" id="olist0155"><list-item id="o0485"><label>19.</label><p id="p0625">Software and datasets.<list list-type="simple" id="olist0160"><list-item id="o0490"><label>a.</label><p id="p0630">Plate reader software: Gen5TM Microplate Data Collection and Analysis Software.</p></list-item><list-item id="o0495"><label>b.</label><p id="p0635">Data analysis software: GraphPad Prism 9.0.0.</p></list-item></list></p></list-item></list></p></sec><sec id="sec4.3"><title>Lenti-pseudovirus production</title><p id="p0640">
<disp-quote id="disp0255"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 6&#x000a0;days</bold></p></disp-quote>
</p><p id="p0645">This step involves packaging SARS-CoV-2 spike pseudoviruses based on the HIV- 1 backbone to evaluate the neutralizing antibody titers in the plasma of immunized mice.</p><p id="p0650">Day 1.<list list-type="simple" id="olist0165"><list-item id="o0500"><label>20.</label><p id="p0655">Seed 2&#x000d7;10<sup>7</sup> HEK 293T cells in T75 flasks to have a confluency of 90% next day at the time of transfection.</p></list-item></list></p><p id="p0660">Day 2.<list list-type="simple" id="olist0170"><list-item id="o0505"><label>21.</label><p id="p0665">Transfection.<list list-type="simple" id="olist0175"><list-item id="o0510"><label>a.</label><p id="p0670">Combine 10&#x000a0;&#x003bc;g psPAX2, 10&#x000a0;&#x003bc;g pLenti-CMV Puro-luc and 5&#x000a0;&#x003bc;g pcDNA3.1&#x000a0;+ S.dCT13 plasmids in 1.5&#x000a0;mL Opti-MEM.</p></list-item><list-item id="o0515"><label>b.</label><p id="p0675">Dilute 75&#x000a0;&#x003bc;g PEI in 1.5&#x000a0;mL Opti-MEM.</p></list-item><list-item id="o0520"><label>c.</label><p id="p0680">Gently mix the diluted PEI to plasmids.</p></list-item><list-item id="o0525"><label>d.</label><p id="p0685">Incubate the PEI-plasmids mixture for 15&#x000a0;min at 25&#x000b0;C.</p></list-item><list-item id="o0530"><label>e.</label><p id="p0690">Carefully add the mixture to the HEK 293T cells.</p></list-item><list-item id="o0535"><label>f.</label><p id="p0695">Replace with 15&#x000a0;mL of fresh complete medium 6&#x000a0;h post transfection.</p></list-item></list></p></list-item></list></p><p id="p0700">Day 3.<list list-type="simple" id="olist0180"><list-item id="o0540"><label>22.</label><p id="p0705">Seed HEK 293T-ACE2 cells into 96-well plates.<list list-type="simple" id="olist0185"><list-item id="o0545"><label>a.</label><p id="p0710">Aspirate the medium and wash HEK 293T-ACE2 cells twice with sterile 1&#x000a0;&#x000d7;&#x000a0;PBS.</p></list-item><list-item id="o0550"><label>b.</label><p id="p0715">Add 2&#x000a0;mL 0.05% trypsin-EDTA to the T75 flask to completely cover cells and incubated at 37&#x000b0;C for 2&#x000a0;min.</p></list-item><list-item id="o0555"><label>c.</label><p id="p0720">Check for cell detachment under a microscope, then add 4&#x000a0;mL of complete medium to stop the reaction. Collect the liquid in sterile tubes and centrifuge at 500 <italic>g</italic> for 5&#x000a0;min at 25&#x000b0;C.</p></list-item><list-item id="o0560"><label>d.</label><p id="p0725">Aspirate the supernatant and resuspend the cells in 2&#x000a0;mL of complete medium.</p></list-item><list-item id="o0565"><label>e.</label><p id="p0730">Count cells using a cell counter.</p></list-item><list-item id="o0570"><label>f.</label><p id="p0735">Resuspend HEK 293T-ACE2 cells in DMEM containing 5% FBS, and seed 2&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup> cells per well in 96-well plates.</p></list-item><list-item id="o0575"><label>g.</label><p id="p0740">Place plates at the 37&#x000b0;C incubator with 5% CO<sub>2</sub>.</p></list-item></list></p></list-item></list></p><p id="p0745">Day 4.<list list-type="simple" id="olist0190"><list-item id="o0580"><label>23.</label><p id="p0750">Collect the pseudovirus supernatant.<list list-type="simple" id="olist0195"><list-item id="o0585"><label>a.</label><p id="p0755">Transfer the culture medium to a 15&#x000a0;mL sterile centrifuge tube 48&#x000a0;h post transfection.</p></list-item><list-item id="o0590"><label>b.</label><p id="p0760">Purify pseudovirus supernatant by filtration using a 0.45&#x000a0;&#x003bc;m filter.</p></list-item><list-item id="o0595"><label>c.</label><p id="p0765">Store the pseudovirus supernatant at 4&#x000b0;C for 1&#x02013;2&#x000a0;days or at &#x02212;80&#x000b0;C for long-term storage.</p></list-item></list></p></list-item></list><disp-quote id="disp0260"><p><bold><italic>Note:</italic></bold> Avoid repeated freezing and thawing.</p></disp-quote><list list-type="simple" id="olist0200"><list-item id="o0600"><label>24.</label><p id="p0770">Pseudovirus titer determination.<list list-type="simple" id="olist0205"><list-item id="o0605"><label>a.</label><p id="p0775">Add 50&#x000a0;&#x003bc;L pseudovirus to per well of HEK 293T-ACE2 cells, performing three replicates.</p></list-item><list-item id="o0610"><label>b.</label><p id="p0780">Centrifuge the plates for 30&#x000a0;min at 1680 <italic>g</italic> at 25&#x000b0;C.</p></list-item><list-item id="o0615"><label>c.</label><p id="p0785">Incubate at 37&#x000b0;C incubator with 5% CO<sub>2</sub> for 36&#x02013;48 h.</p></list-item></list></p></list-item></list></p><p id="p0790">Day 6.<list list-type="simple" id="olist0210"><list-item id="o0620"><label>25.</label><p id="p0795">Luciferase luminescence measurement.<list list-type="simple" id="olist0215"><list-item id="o0625"><label>a.</label><p id="p0800">Discard the supernatant after incubation.</p></list-item><list-item id="o0630"><label>b.</label><p id="p0805">Add 100&#x000a0;&#x003bc;L of lysis buffer, and incubate for 15&#x000a0;min at 25&#x000b0;C.</p></list-item><list-item id="o0635"><label>c.</label><p id="p0810">Add 100&#x000a0;&#x003bc;L of luciferin substrate to the lysate and allow to react for 1&#x02013;2 s.</p></list-item><list-item id="o0640"><label>d.</label><p id="p0815">Transfer 100&#x000a0;&#x003bc;L of the mixture to a white plate and measure luciferase luminescence using a luminometer.</p></list-item><list-item id="o0645"><label>e.</label><p id="p0820">Dilute the virus based on the measured luminescence values to achieve a readout that is 100&#x02013;500 times above the background.</p></list-item></list></p></list-item></list></p></sec><sec id="sec4.4"><title>Lentiviral luciferase-based pseudovirus neutralization assay</title><p id="p0825">
<disp-quote id="disp0265"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 4&#x000a0;days</bold></p></disp-quote>
</p><p id="p0830">This step involves co-incubating the SARS-CoV-2 spike pseudovirus with plasma from immunized mice to detect the neutralizing antibody titers.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Plasma dilution for the neutralization assay</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Sample ID</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th><th>NPC</th><th>NVC</th></tr></thead><tbody><tr><td>A</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>1:20</td><td>N/A</td><td>N/A</td></tr><tr><td>B</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>1:60</td><td>N/A</td><td>N/A</td></tr><tr><td>C</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>1:180</td><td>N/A</td><td>N/A</td></tr><tr><td>D</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>1:540</td><td>N/A</td><td>N/A</td></tr><tr><td>E</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>1:1620</td><td>N/A</td><td>N/A</td></tr><tr><td>F</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>1:4860</td><td>N/A</td><td>N/A</td></tr><tr><td>G</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>1:14580</td><td>N/A</td><td>N/A</td></tr><tr><td>H</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>1:43740</td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><fn><p>NPC, no plasma control (virus and cells only); NVC, No virus control (cells only).</p></fn></table-wrap-foot></table-wrap></p><p id="p0835">Day 1.<list list-type="simple" id="olist0220"><list-item id="o0650"><label>26.</label><p id="p0840">Seed HEK 293T-ACE2 cells in 96-well plates.<list list-type="simple" id="olist0225"><list-item id="o0655"><label>a.</label><p id="p0845">Gently aspirate the medium from the culture flask and wash HEK 293T-ACE2 cells twice with sterile 1&#x000a0;&#x000d7;&#x000a0;PBS.</p></list-item><list-item id="o0660"><label>b.</label><p id="p0850">Add 2&#x000a0;mL of 0.05% trypsin-EDTA to the T75 flask, covering the cells completely, and incubate at 37&#x000b0;C for 2&#x000a0;min.</p></list-item><list-item id="o0665"><label>c.</label><p id="p0855">Check under a microscope for cell detachment. Add 4&#x000a0;mL of complete medium to stop the trypsin-EDTA reaction. Collect the liquid in sterile tubes and centrifuge at 500 <italic>g</italic> for 5&#x000a0;min at 25&#x000b0;C.</p></list-item><list-item id="o0670"><label>d.</label><p id="p0860">Aspirate the supernatant and resuspend the cells in 2&#x000a0;mL of complete medium.</p></list-item><list-item id="o0675"><label>e.</label><p id="p0865">Count the cells using a cell counter.</p></list-item><list-item id="o0680"><label>f.</label><p id="p0870">Resuspend HEK 293T-ACE2 cells in DMEM containing 5% FBS, and seed 2&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup> cells per well into a 96-well tissue culture plate.</p></list-item><list-item id="o0685"><label>g.</label><p id="p0875">Incubate plates at 37&#x000b0;C with 5% CO<sub>2</sub>.</p></list-item></list></p></list-item></list></p><p id="p0880">Day 2.<list list-type="simple" id="olist0230"><list-item id="o0690"><label>27.</label><p id="p0885">Dilute the plasma.<list list-type="simple" id="olist0235"><list-item id="o0695"><label>a.</label><p id="p0890">Add 90&#x000a0;&#x003bc;L of FBS-free DMEM to row 1 of a new 96-well round- bottom plate and 60&#x000a0;&#x003bc;L to rows 2&#x02013;8. Add 60&#x000a0;&#x003bc;L of FBS-free DMEM to column 11 and 120&#x000a0;&#x003bc;L to column 12.</p></list-item><list-item id="o0700"><label>b.</label><p id="p0895">Add 10&#x000a0;&#x003bc;L of plasma to each well in row 1 (except for columns 11 and 12), achieving a starting dilution of 1:20. Mix thoroughly.</p></list-item><list-item id="o0705"><label>c.</label><p id="p0900">Transfer 30&#x000a0;&#x003bc;L from row 1 to row 2 and mix thoroughly. Repeat this dilution process for rows 2 through 8, discarding 30&#x000a0;&#x003bc;L from the final row (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). Each 96-well plate can accommodate 10 samples.</p></list-item></list></p></list-item><list-item id="o0710"><label>28.</label><p id="p0905">Thaw the pseudovirus. Remove pseudovirus aliquots from the &#x02212;80&#x000b0;C freezer and allow them to reach 25&#x000b0;C.</p></list-item><list-item id="o0715"><label>29.</label><p id="p0910">Transfer 60&#x000a0;&#x003bc;L of pseudovirus to the diluted plasma in the 96-well round- bottom microplate (except in NVC wells). Mix thoroughly.</p></list-item><list-item id="o0720"><label>30.</label><p id="p0915">Centrifuge the plates at 1680 <italic>g</italic> for 30&#x000a0;min at 20&#x000b0;C. Incubate the plates at 37&#x000b0;C with 5% CO<sub>2</sub>&#x000a0;for 36&#x02013;48 h.</p></list-item></list></p><p id="p0925">Day 4.<list list-type="simple" id="olist0240"><list-item id="o0725"><label>31.</label><p id="p0930">Luciferase luminescence measurement.<list list-type="simple" id="olist0245"><list-item id="o0730"><label>a.</label><p id="p0935">After incubation, discard the supernatant.</p></list-item><list-item id="o0735"><label>b.</label><p id="p0940">Add 100&#x000a0;&#x003bc;L of lysis buffer to each well and incubate for 15&#x000a0;min at 25&#x000b0;C.</p></list-item><list-item id="o0740"><label>c.</label><p id="p0945">Add 100&#x000a0;&#x003bc;L of luciferin substrate to the lysate and allow to react for 1&#x02013;2 s.</p></list-item><list-item id="o0745"><label>d.</label><p id="p0950">Transfer 100&#x000a0;&#x003bc;L of the mixture to a white plate and measure luciferase luminescence using a luminometer.</p></list-item></list></p></list-item><list-item id="o0750"><label>32.</label><p id="p0955">NT50 interpolation.<list list-type="simple" id="olist0250"><list-item id="o0755"><label>a.</label><p id="p0960">Use GraphPad Prism9.0.0 to interpolate the NT50 titers.</p></list-item><list-item id="o0760"><label>b.</label><p id="p0965">Define the SARS-CoV-2 pseudovirus neutralization titers as the plasma dilution at which a 50% reduction in relative light units (RLU) is observed compared to the difference between the NVC and NPC wells.</p></list-item></list></p></list-item></list></p></sec></sec><sec id="sec5"><title>Expected outcomes</title><p id="p0970">The 239F cell cultures were centrifuged to remove cells and cellular debris, followed by incubation with Ni-NTA His-Tag Purification Agarose. A low concentration of imidazole was applied to elute non-specific proteins, while higher concentrations of imidazole (typically 100&#x02013;300&#x000a0;mM) were used to elute the target proteins. This method was effective for the elution of WA01-RBD. The molecular weight of the primary bands was confirmed using SDS-PAGE (stained with 1% Coomassie Blue R250), with the expected size of 28&#x000a0;kDa (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>SDS-PAGE to detect WA01-RBD protein expression and purification</p><p>Samples eluted with different imidazole concentrations were detected by 4%&#x02013;20% SDS-PAGE.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0975">Each group of five mice was immunized with either Ad5-EGFP or Ad5-S. Four weeks post-immunization, blood was collected, and plasma was separated for the detection of S-specific binding and neutralizing antibodies (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>A and 3B). Mice immunized with Ad5-S exhibited significantly higher titers of S-specific binding and neutralizing antibodies compared to the control group immunized with Ad5-EGFP.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Humoral response at week 4 post-vaccination with Ad5-vectored vaccines</p><p>(A) Plasma S-specific binding antibody responses were quantified by ELISA at week 4 post-vaccination.</p><p>(B) Plasma neutralizing activity of elicited antibody responses were assessed at week 4 after vaccination using pseudovirus SARS- CoV-2 neutralization assays. Data were analyzed using Mann-Whitney tests: (A) <italic>p</italic>&#x000a0;= 0.0079&#x02217;&#x02217; and (B) <italic>p</italic>&#x000a0;= 0.0079&#x02217;&#x02217;.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec6"><title>Limitations</title><p id="p0980">Due to limited serum available from the mice, the lower limit of detection is set at 1:20. This threshold could be improved with a larger serum volume but ensures consistent and reproducible results within the constraints of this experiment.</p><p id="p0985">It&#x02019;s important to note that focusing exclusively on RBD-specific antibodies may not provide a complete picture of the antibody response to SARS-CoV-2. Since the RBD represents only part of the spike protein, assays utilizing the full-length spike protein might offer a more comprehensive assessment of the immune response.</p><p id="p0990">Additionally, pseudovirus-based assays, while valuable, may yield results that differ from assays using live viruses or <italic>in&#x000a0;vivo</italic> models. Therefore, these findings should be interpreted with caution and, if possible, compared with results from assays involving authentic viruses for greater accuracy.</p></sec><sec id="sec7"><title>Troubleshooting</title><sec id="sec7.1"><title>Problem 1</title><p id="p0995">High background or signal in ELISA (related to Step 18c).</p></sec><sec id="sec7.2"><title>Potential solutions</title><p id="p1000">If the negative control group shows a higher signal, possible causes include.<list list-type="simple" id="ulist0015"><list-item id="u0025"><label>&#x02022;</label><p id="p1005">Insufficient washing or residual solution in the wells after washing. Increase the wash solution volume to 300&#x000a0;&#x003bc;L per well. After each wash, tap the plate firmly to remove residual liquid on a clean paper towel. Repeat 3 times.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p1010">Over-incubation. Prolonged incubation can increase background signals without improving sensitivity, as the TMB solution will react over time. Follow the recommended protocol incubation times strictly.</p></list-item></list></p></sec><sec id="sec7.3"><title>Problem 2</title><p id="p1015">Low or unstable signal in ELISA (related to Step 18c).</p></sec><sec id="sec7.4"><title>Potential solutions</title><p id="p1020">Possible causes include improper pipetting technique or the introduction of air bubbles, which affect volume accuracy. To avoid these issues, ensure proper pipetting and prevent cross-contamination between samples.<list list-type="simple" id="ulist0020"><list-item id="u0035"><label>&#x02022;</label><p id="p1025">Ensure reagents are not expired, as this may cause variable results.</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p1030">Allow the TMB color developer to reach ambient temperature before use.</p></list-item><list-item id="u0045"><label>&#x02022;</label><p id="p1035">Protect plates from light during incubation steps to maintain assay accuracy.</p></list-item></list></p></sec><sec id="sec7.5"><title>Problem 3</title><p id="p1040">Low pseudovirus titer (related to Step 25d).</p></sec><sec id="sec7.6"><title>Potential solutions</title><p id="p1045">
<list list-type="simple" id="ulist0025"><list-item id="u0050"><label>&#x02022;</label><p id="p1050">Ensure that the plasmids used for virus production is of high quality and concentration.</p></list-item><list-item id="u0055"><label>&#x02022;</label><p id="p1055">Ensure that the cells used for transfection are in good growth condition and have reached at least 90% confluency.</p></list-item><list-item id="u0060"><label>&#x02022;</label><p id="p1060">Six hours after transfection, replace the medium to promote robust cell growth and higher virus yields.</p></list-item><list-item id="u0065"><label>&#x02022;</label><p id="p1065">Immediately conduct the viral titer assay after harvesting the pseudovirus.</p></list-item><list-item id="u0070"><label>&#x02022;</label><p id="p1070">Handle the pseudovirus carefully, avoid vigorous shaking, and minimize time at 25&#x000b0;C, as the pseudovirus is sensitive to physical stress and heat. Avoid repeated freeze-thaw cycles and use thawed virus immediately.</p></list-item></list>
</p></sec><sec id="sec7.7"><title>Problem 4</title><p id="p1075">Fluctuations in luminescence values during the neutralization assay (related to Step 31d).</p></sec><sec id="sec7.8"><title>Potential solutions</title><p id="p1080">
<list list-type="simple" id="ulist0030"><list-item id="u0075"><label>&#x02022;</label><p id="p1085">When performing plasma gradient dilutions, ensure precise sample additions and liquid handling.</p></list-item><list-item id="u0080"><label>&#x02022;</label><p id="p1090">Avoid creating bubbles while mixing.</p></list-item><list-item id="u0085"><label>&#x02022;</label><p id="p1095">When incubating the plasma-virus mixture or transduced cell plates, avoid stacking 96-well microplates to ensure even heating across all wells.</p></list-item><list-item id="u0090"><label>&#x02022;</label><p id="p1100">When adding the plasma-virus mixture to the cells, do so gently to avoid detaching cells. Similarly, when discarding waste liquid during sample collection, handle with care to prevent cell detachment.</p></list-item></list>
</p></sec></sec><sec id="sec8"><title>Resource availability</title><sec id="sec8.1"><title>Lead contact</title><p id="p1105">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Jingyou Yu (<email>yu_jingyou@gzlab.ac.cn</email>).</p></sec><sec id="sec8.2"><title>Technical contact</title><p id="p1110">Further information and requests for resources and reagents should be directed to and will be fulfilled by the technical contacts, Yao Zhang (<email>zhang_yao2@gzlab.ac.cn</email>) and Shixiong Li (<email>li_shixiong@gzlab.ac.cn</email>).</p></sec><sec id="sec8.3"><title>Materials availability</title><p id="p1115">This study did not generate any unique reagents.</p></sec><sec sec-type="data-availability" id="sec8.4"><title>Data and code availability</title><p id="p1120">This study did not generate/analyze any datasets or code.</p></sec></sec><sec id="sec10"><title>Acknowledgments</title><p id="p1130">We thank the members of Yu lab for their advice, assistance, and reagents. This work was supported by the <funding-source id="gs1">Major Project of Guangzhou National Laboratory</funding-source> (<award-id award-type="grant" rid="gs1">GZNL2023A01009</award-id> and <award-id award-type="grant" rid="gs1">GZNL2023A01005</award-id> to J.Y.); the <funding-source id="gs2">National Natural Science Foundation of China</funding-source> (NSFC <award-id award-type="grant" rid="gs2">82371831</award-id> to J.Y.); the Joint Project by Guangzhou National Laboratory and State Key Laboratory of Respiratory Disease, Guangzhou Medical University (GZNL2024B01006 to J.Y.); and the <funding-source id="gs3">Young Talent Program of China</funding-source> (<award-id award-type="grant" rid="gs3">HJJH22-004</award-id> to J.Y.).</p></sec><sec id="sec11"><title>Author contributions</title><p id="p1135">Conceptualization, J.Y.; investigation, Y.Z., S.L., and J.Y.; writing&#x000a0;&#x02013; original draft, Y.Z. and S.L.; writing&#x000a0;&#x02013; review and editing, J.Y..; funding acquisition, J.Y.; supervision, J.Y.; Y.Z. and S.L. contributed equally to this work.</p></sec><sec sec-type="COI-statement" id="sec12"><title>Declaration of interests</title><p id="p1140">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name><surname>Peter</surname><given-names>L.</given-names></name><name><surname>Mercado</surname><given-names>N.B.</given-names></name><name><surname>McMahan</surname><given-names>K.</given-names></name><name><surname>Mahrokhian</surname><given-names>S.H.</given-names></name><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Chandrashekar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title><source>Science (New York, N.Y.)</source><volume>369</volume><year>2020</year><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1126/science.abc6284</pub-id><pub-id pub-id-type="pmid">32434945</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Jacob-Dolan</surname><given-names>C.</given-names></name><name><surname>Feldman</surname><given-names>J.</given-names></name><name><surname>McMahan</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Zahn</surname><given-names>R.</given-names></name><name><surname>Wegmann</surname><given-names>F.</given-names></name><name><surname>Schuitemaker</surname><given-names>H.</given-names></name><name><surname>Schmidt</surname><given-names>A.G.</given-names></name><name><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Coronavirus- Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV- 2 Vaccination and Infection</article-title><source>J.&#x000a0;Virol.</source><volume>95</volume><year>2021</year><fpage>e00117-21</fpage><pub-id pub-id-type="doi">10.1128/JVI.00117-21</pub-id><pub-id pub-id-type="pmid">33692201</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zi</surname><given-names>Q.</given-names></name><name><surname>Mou</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant</article-title><source>iScience</source><volume>27</volume><year>2024</year><object-id pub-id-type="publisher-id">110405</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2024.110405</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Collins</surname><given-names>N.D.</given-names></name><name><surname>Mercado</surname><given-names>N.B.</given-names></name><name><surname>McMahan</surname><given-names>K.</given-names></name><name><surname>Chandrashekar</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Anioke</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Giffin</surname><given-names>V.M.</given-names></name><name><surname>Hope</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques</article-title><source>J.&#x000a0;Virol.</source><volume>96</volume><year>2022</year><object-id pub-id-type="publisher-id">e0159921</object-id><pub-id pub-id-type="doi">10.1128/JVI.01599-21</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Martinez</surname><given-names>D.R.</given-names></name><name><surname>Schaefer</surname><given-names>A.</given-names></name><name><surname>Mahrokhian</surname><given-names>S.H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Nampanya</surname><given-names>F.</given-names></name><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2</article-title><source>J.&#x000a0;Virol.</source><volume>95</volume><year>2021</year><object-id pub-id-type="publisher-id">e0097421</object-id><pub-id pub-id-type="doi">10.1128/JVI.00974-21</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zi</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Mou</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Omicron breakthrough infected individuals show enhanced nasal antibody responses and preserved T&#x000a0;cell responses against the EG.5.1 and BA.2.86</article-title><source>J.&#x000a0;Med. Virol.</source><volume>96</volume><year>2024</year><object-id pub-id-type="publisher-id">e29537</object-id><pub-id pub-id-type="doi">10.1002/jmv.29537</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Heterogeneous hybrid immunity against Omicron variant JN.1 at 11&#x000a0;months following breakthrough infection</article-title><source>Signal Transduct. Target. Ther.</source><volume>9</volume><year>2024</year><fpage>180</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01898-x</pub-id><pub-id pub-id-type="pmid">39025834</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Martinot</surname><given-names>A.J.</given-names></name><name><surname>McMahan</surname><given-names>K.</given-names></name><name><surname>Mercado</surname><given-names>N.B.</given-names></name><name><surname>Peter</surname><given-names>L.</given-names></name><name><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Maliga</surname><given-names>Z.</given-names></name><name><surname>Nekorchuk</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection protects against rechallenge in rhesus macaques</article-title><source>Science (New York, N.Y.)</source><volume>369</volume><year>2020</year><fpage>812</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1126/science.abc4776</pub-id><pub-id pub-id-type="pmid">32434946</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Gebre</surname><given-names>M.S.</given-names></name><name><surname>Bondzie</surname><given-names>E.A.</given-names></name><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Jacob-Dolan</surname><given-names>C.</given-names></name><name><surname>Martinez</surname><given-names>D.R.</given-names></name><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays</article-title><source>J.&#x000a0;Virol.</source><volume>95</volume><year>2021</year><fpage>e00044-21</fpage><pub-id pub-id-type="doi">10.1128/JVI.00044-21</pub-id><pub-id pub-id-type="pmid">33727331</pub-id>
</element-citation></ref></ref-list></back></article>